Theravance signs cardiovascular drug development deal with Merck

Merck & Co. and Theravance agreed to develop the latter's small molecule therapeutic candidates for hypertension and heart failure. The agreement grants Merck exclusive, worldwide rights to Theravance's drug candidates. Theravance will receive $5 million upfront and as much as $148 million in milestone fees for the initial indication plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX